港股異動丨微創機器人-B(2252.HK)大漲超12%創新高 市值首次站上600億港元
格隆匯11月12日丨微創機器人-B(2252.HK)大幅拉昇漲超12%,高見63.8港元創歷史新高價,總市值站上600億港元。該股上市9日不斷拉昇上揚,累計漲幅高達60%。公司是全球行業中唯一一家擁有覆蓋五大主要手術專科(即腔鏡、骨科、泛血管、經自然腔道及經皮穿刺手術)產品組合的公司。隨着診斷技術進步及人均可支配收入增加,患者逐漸願意尋求造成微創傷的治療方法。因此,對手術機器人的需求不斷增加。業內人士預期未來中國手術機器人將為外科領域帶來極大精進。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.